Theriva Biologics Inc. (TOVX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE MKT
Market Cap: $6.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
Theriva Biologics Inc. (TOVX) Competitors
The companies most similar to Theriva Biologics are GT Biopharma (GTBP), Tempest Therapeutics (TPST) and Reviva Pharmaceuticals Holdings (RVPH). By market cap, Theriva Biologics ranks 8th of the 13 companies on this page; Tvardi Therapeutics (TVRD) is the largest at $15.74M.
Peer Comparison
TOVX's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Theriva Biologics (TOVX) | $6.61M | N/A | 21.5x | 0.0% | -52.3% | 0.0% | 0.00% |
| GT Biopharma Inc (GTBP) | $7.67M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tempest Therapeutics Inc (TPST) | $7.64M | N/A | N/A | 0.0% | -783.6% | 0.0% | 0.00% |
| Reviva Pharmaceuticals Holdings Inc. (RVPH) | $4.63M | N/A | N/A | 0.0% | -90.2% | 0.0% | 0.00% |
| Processa Pharmaceuticals Inc (PCSA) | $5.20M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| FibroBiologics, Inc. Common Stock (FBLG) | $6.57M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Moleculin Biotech Inc (MBRX) | $8.02M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Marker Therapeutics Inc (MRKR) | $14.51M | N/A | 14.5x | -245.5% | N/A | -51.0% | 0.00% |
| Kiora Pharmaceuticals Inc (KPRX) | $5.44M | N/A | 6.2x | 0.0% | N/A | 0.0% | 0.00% |
| Intensity Therapeutics, Inc. Common stock (INTS) | $10.17M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Tvardi Therapeutics, Inc. (TVRD) | $15.74M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| GRI Bio Inc. (GRI) | $3.72M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $7.65M | N/A | 10.3x | 0.0% | -436.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Theriva Biologics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| GT Biopharma Inc (GTBP) | GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its... | GTBP competitors |
| Tempest Therapeutics Inc (TPST) | Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated... | TPST competitors |
| Reviva Pharmaceuticals Holdings Inc. (RVPH) | Reviva Pharmaceuticals Holdings Inc. (RVPH) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for central nervous... | RVPH competitors |
| Processa Pharmaceuticals Inc (PCSA) | Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients... | PCSA competitors |
| FibroBiologics, Inc. Common Stock (FBLG) | FibroBiologics, Inc. is an innovative biotechnology company dedicated to advancing regenerative medicine through its proprietary fibroblast cell technology... | FBLG competitors |
| Moleculin Biotech Inc (MBRX) | Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant... | MBRX competitors |
| Marker Therapeutics Inc (MRKR) | Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based... | MRKR competitors |
| Kiora Pharmaceuticals Inc (KPRX) | Kiora Pharmaceuticals Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for ocular diseases and neurodegenerative... | KPRX competitors |
| Intensity Therapeutics, Inc. Common stock (INTS) | Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. | INTS competitors |
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Tvardi Therapeutics, Inc. (TVRD) | Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet... | TVRD competitors |
| GRI Bio Inc. (GRI) | GRI Bio Inc. is an innovative biotechnology company focused on leveraging microbiome technology to develop cutting-edge therapeutics in immunology and oncology. | GRI competitors |
Frequently Asked Questions About TOVX
Who are Theriva Biologics' main competitors?
The companies most similar to Theriva Biologics include GT Biopharma (GTBP), Tempest Therapeutics (TPST), Reviva Pharmaceuticals Holdings (RVPH), Processa Pharmaceuticals (PCSA) and FibroBiologics, Inc. Common Stock (FBLG), listed from the closest match.
Who is Theriva Biologics' biggest competitor?
Tvardi Therapeutics (TVRD) is the largest of the similar companies at $15.74M; GT Biopharma (GTBP) is the closest match by business profile, size, sector and industry.
How does TOVX stock compare with its competitors?
TOVX's P/S is 21.5x against a peer median of 10.3x; its net margin is 0.0% against a peer median of 0.0%.
Which of Theriva Biologics' competitors pays a higher dividend?
Theriva Biologics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Theriva Biologics bigger than its competitors?
No. Theriva Biologics is 8th by market cap among the 13 companies on this page; the largest is Tvardi Therapeutics (TVRD) at $15.74M.
TOVX pages: Overview, Earnings, Forecast, Financials, Competitors